Clinical Study Report Synopses
Clinical Study Reports (CSRs) are often created as part of the process of submitting applications for new medical treatments to regulators. CSRs answer questions such as: Why was the trial done? What were the important questions asked in the trial? What were the results? CSRs also include details on the course of treatment for patients, the medical information collected from the patients as part of the research, and demographic data, as well as other kinds of information to explain how the trial was conducted and results were analyzed.
Because CSRs contain information that could be valuable to researchers, Pfizer makes synopses of CSRs publicly available on this website. A synopsis is a high-level summary of the CSR.
Synopses will be posted for trials either initiated after Sept. 27, 2007, or trials initiated on or before that date that were ongoing as of Dec. 26, 2007. To access the synopses that have been posted to date, press the "Show Results" button to see the full list, or filter the results using the fields below.
* The NCT Number is the ClinicalTrials.gov unique identifier for a specific study.
Research Rising: Recognizing Clinical Trials Day 2026
Before a breakthrough reaches a patient, it moves through years of research, which is shaped by questions, tested through data, and strengthened by collaboration.At Pfizer, that work is always in motion.
How AI Is Already Reshaping Cancer Care
When treating cancer, few things are more precious than time.
February Social Media Round-Up—World Cancer Day, Science Will Win, and More
The groundhog may have predicted six more weeks of winter, but here at Pfizer we’re predicting blue skies ahead as we wrap up another great month.We kicked off February with the launch of season six of “Science Will Win”—Pfizer’s award-winning podcast, announced the launch of The Empowering Women in
Powered by Purpose: Celebrating Clinical Trials Day 2025
Pfizer has been in the business of breakthroughs for nearly two centuries, and while our success represents the shared work of thousands of our dedicated employees, none of the advancements for which we are known were made possible through our efforts alone.
The Next Era of Decentralized Clinical Trials: The Clinical Trial Anywhere Model
During the early months of 2020, decentralized modalities to conduct clinical trials went mainstream as a solution to a short-term problem: how to continue clinical trials amid pandemic closures.
July Social Media Round-Up—Summer Interns, 175 Days of Good, and More
Pfizer jumped into the summer holidays with another eventful month.
Clinical Trial Innovation: Putting the Patient First in Clinical Trial Design
Every day, across the United States and around the world, scientists are developing potential new medicines and vaccines that could change lives.
May Social Media Round-Up—Clinicals Trials Day, the TIME 100, and the Future of Cancer Care
The month of May not only brought flowers, but also noteworthy celebrations at Pfizer.
The Importance of Returning Clinical Trial Data to Participants
Clinical trial participants are at the heart of medical research, and it’s with their help that Pfizer is able to bring life-changing treatments to patients.But, until recently, clinical trial sponsors like Pfizer have not been equipped to provide participants with their own personal clinical trial
September Social Media Round-Up—DEI, CMO, and Rocky Mount Resumes
This September, Albert Bourla, Pfizer’s CEO, attended Black Corporate Directors Conference to discuss minority representation across all sectors, and our social roundup starts with his thoughts on their mission.
July Social Media Round-Up—Rocky Mount Update, Rady Johnson Honored, and Vaccine Progress
On July 20, a tornado touched down in North Carolina, injuring 16 people and damaging a Pfizer plant in Rocky Mount, one of the largest manufacturers of sterile injectable drugs in the world.
Listen Now—Science Will Win Season 2 Takes on Breast Cancer
Science Will Win, one of Pfizer’s premiere podcasts, is back! This season we’ll explore the advancements and the challenges of cancer treatments, particularly in the breast cancer space.
Albert Bourla Reflects on the One Year Anniversary of the COVID-19 Pandemic
One year. That’s how long it has been since the World Health Organization declared COVID-19 a global pandemic. Sometimes it feels like the year went by in the blink of an eye.
Translating Technical Language into Plain Language for Clinical Trials
"Adjuvant therapy." "Pharmacologic effect." "Standard-of-care." These aren't terms used by most people in everyday conversation. But this kind of medical terminology has long been a part of clinical trial summaries, making it daunting for many people to understand what they're reading.
Do You Have What It Takes to Join a Phase 1 Clinical Trial?
“Life's most persistent and urgent question is: What are you doing for others?” ~ Martin Luther King, Jr. For some, volunteering at their local food bank is a preferred way to give back. Some donate money to organizations or non-profits they believe in. Others donate blood.
Doing Better: Increasing Diversity in Clinical Trials
Diversity in clinical trials is key to equitable health outcomes. Increasingly, clinicians, researchers and patients are realizing that a lack of diversity in clinical trial participants may contribute to the stubborn persistence of health disparities, such as the fact that Black Americans are 30%
The Phases of a Clinical Trial
Understanding the Phases of Clinical Trials Prescription drugs don’t just show up on pharmacy shelves one day.
Differences Can Make a Big Difference
People from different racial and ethnic groups have different biological responses to both diseases and their treatment.
Exploring the Manufacturing and Testing Processes of Pharmaceuticals
When a doctor prescribes you a medicine, how does she know it could be helpful?
Clinical Trial Practices—Safeguards in Research
If you or a loved one is considering joining a clinical trial, you may be happy to know that research studies today have strict safeguards, standards of ethics, and are highly regulated.